The highly selective partial agonist at D1 and D5 receptors significantly improves motor function in patients recently ...

Bromocriptine is a sympatholytic D2-dopamine agonist that has been approved for the treatment of type 2 diabetes. Based on animal and human studies, timed bromocriptine administration within 2 h ...

Both compounds can be distinguished from typical D 2 agonists, however, because they do not cause behavioral signs associated with activation of either normosensitive or supersensitive ...

For patients with Parkinson disease with motor fluctuations, the oral once-daily, selective D1/D5 partial dopamine agonist tavapadon as an adjunct to levodopa increases total daily ON time vs placebo.